Editas Medicine will sell its cancer cell therapy work to privately held Shoreline Biosciences as part of a company-wide restructuring that’s already led to layoffs and cutbacks in spending.

Just 10 days after announcing plans to let go of its iNK programs as part of a major portfolio and workforce restructuring, Editas Medicine has found a buyer for the cell technologies in the form of Shoreline Biosciences.

Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.

Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.

China’s BeiGene has been busy on the oncology front in recent years, looking to keep up with the pack with one late-stage PD-1 on the way to a filing and a slate of small deals fleshing out the pipeline. Now, with its eyes on the horizon, the drugmaker has snared an early-stage pact for a clutch of next-gen cell therapies.